A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance dosing for those with early Alzheimer’s disease, Eisai Co. Ltd. and Biogen Inc.

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...

Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a ...

Cortec GmbH implanted its brain-computer interface (BCI) system, Brain Interchange, into a stroke patient in late July, ...

At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...

Around 10 million people globally live with the life-threatening human T-cell lymphotropic virus type-1 (HTLV-1), yet it ...

Radiopharm Theranostics Ltd. announced that the U.S. FDA has cleared the IND application for betabart (RV-01), its Lu177-B7H3 ...

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license ...

The U.S. Federal Trade Commission announced a $14.6 million grant it received for an upgrade of its IT infrastructure. The ...

As biotech zombies with failed programs and money in hand go, Galapagos NV is a notable example, with a number of misses in ...

Researchers from Insmed Inc. presented findings on INM-901, a novel synthetic cannabinoid analogue, demonstrating its effects ...

Formation Bio Inc. has licensed worldwide rights to Imidomics Inc.’s potentially first-in-class anti-CD226 monoclonal ...